Chargement en cours...
Efficacy of Ruxolitinib for Myelofibrosis
INTRODUCTION: The discovery of the activating JAK2V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors. The first such inhibitor to enter clinical trials was ruxolitinib. This review summarizes pre-clinical and clinical data of ruxolitinib in MF. AREAS COVERED...
Enregistré dans:
| Publié dans: | Expert Opin Pharmacother |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4824286/ https://ncbi.nlm.nih.gov/pubmed/24856675 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2014.923404 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|